Home » Topics » Regulatory

Regulatory
RSS

NDA for subcutaneous Repronex approved by FDA

Aug. 31, 1999

Temodal approved in E.U. for treatment of recurrent anaplastic astrocytoma

Aug. 27, 1999

InterMune files BLA for Actimmune for treatment of osteopetrosis

Aug. 25, 1999

Bio-Technology General granted additional patent allowance for oxandrolone

Aug. 24, 1999

QLT begins phase II trial for psoriasis treatment

Aug. 24, 1999

Chiron initiates phase III study of Proleukin for HIV

Aug. 23, 1999

FDA approves Organon's short-acting neuromuscular blocker Raplon

Aug. 19, 1999

FDA approves Cleocin vaginal ovules for treatment of bacterial vaginosis

Aug. 19, 1999

Etanercept trial results in psoriatic arthritis announced

Aug. 18, 1999

Preclinical study results indicate efficacy of thiazolidinediones in IBD

Aug. 16, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Nov. 8, 2024.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for November 8, 2024.
Sales balloon for GLP-1 drugs from Novo Nordisk, Eli Lilly
BioWorld
Nearly $3.8 billion was earned by Novo Nordisk A/S and Eli Lilly and Co. in the third quarter for their glucagon-like peptide-1 (GLP-1) drugs to treat obesity....
Regulatory actions for Oct. 31, 2024
BioWorld
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Capsida, Electra,...
Australia reimburses Vazkepa a decade after US approval
BioWorld
For the first time, Australians have access to CSL Inc.’s Vazkepa (icosapent ethyl/Vascepa) for managing cardiovascular disease more than a decade after the drug...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.